Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has received an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $21.3750.

KROS has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research note on Monday, December 22nd. Bank of America upped their price objective on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, November 28th. TD Cowen upgraded shares of Keros Therapeutics to a “hold” rating in a research report on Friday, December 19th. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th.

Keros Therapeutics Trading Down 1.5%

NASDAQ KROS opened at $21.03 on Friday. The company has a 50-day moving average price of $18.06 and a two-hundred day moving average price of $15.85. The stock has a market cap of $640.78 million, a price-to-earnings ratio of 13.66, a price-to-earnings-growth ratio of 0.26 and a beta of 0.89. Keros Therapeutics has a 52 week low of $9.12 and a 52 week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The business had revenue of $14.26 million during the quarter, compared to the consensus estimate of $4.22 million. During the same period in the previous year, the firm posted ($1.41) earnings per share. The business’s revenue was up 3585.6% on a year-over-year basis. As a group, equities research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of Keros Therapeutics stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of KROS. Corebridge Financial Inc. lifted its holdings in Keros Therapeutics by 6.4% in the 1st quarter. Corebridge Financial Inc. now owns 16,212 shares of the company’s stock valued at $165,000 after acquiring an additional 972 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in shares of Keros Therapeutics by 8.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares during the last quarter. UBS Group AG raised its holdings in shares of Keros Therapeutics by 1.1% in the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock worth $1,643,000 after purchasing an additional 1,091 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after purchasing an additional 1,888 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey lifted its stake in Keros Therapeutics by 29.7% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 8,257 shares of the company’s stock valued at $110,000 after purchasing an additional 1,892 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.